Stockreport

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Altimmune Inc ( NASDAQ:ALT ) has fully enrolled its Phase 2B impact trial for PTI IN MS, with top-line efficacy data expected in Q2 2025. The company achieved alignme [Read more]